Cingulate Announces Complete Enrollment in Human Formulation Study of CTx-2103 for the Treatment of Anxiety Disorders - BioSpace

Submitted by Anonymous (not verified) on Tue, 05/24/2022 - 11:12

Cingulate Announces Complete Enrollment in Human Formulation Study of CTx-2103 for the Treatment of Anxiety Disorders  BioSpace